Kenneth W. Mahaffey
#113,800
Most Influential Person Now
Kenneth W. Mahaffey's AcademicInfluence.com Rankings
Kenneth W. Mahaffeyphilosophy Degrees
Philosophy
#4865
World Rank
#7528
Historical Rank
Logic
#2238
World Rank
#3185
Historical Rank
Download Badge
Philosophy
Kenneth W. Mahaffey's Degrees
- Doctorate Medicine University of California, San Francisco
- Masters Clinical Research Duke University
Why Is Kenneth W. Mahaffey Influential?
(Suggest an Edit or Addition)Kenneth W. Mahaffey's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. (2012) (7528)
- Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. (2011) (5296)
- Ticagrelor versus clopidogrel in patients with acute coronary syndromes. (2009) (4964)
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (2017) (3090)
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. (2019) (2717)
- Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. (2004) (833)
- Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. (2012) (795)
- Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation. (2019) (763)
- Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. (2012) (718)
- Effect of platelet inhibition with cangrelor during PCI on ischemic events. (2013) (705)
- Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology ( ESC ) (2012) (639)
- Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. (2005) (637)
- Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. (2008) (593)
- Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. (2011) (591)
- Intravenous platelet blockade with cangrelor during PCI. (2009) (590)
- ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. (2008) (581)
- ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use (2010) (577)
- Myonecrosis after revascularization procedures. (1998) (572)
- Platelet inhibition with cangrelor in patients undergoing PCI. (2009) (571)
- 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). (2015) (560)
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) (558)
- Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. (1999) (552)
- ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. (2008) (509)
- Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. (2011) (491)
- SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. (2019) (464)
- Ticagrelor Versus Clopidogrel in Symptomatic Peripheral Artery Disease (2017) (411)
- Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. (2018) (410)
- Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. (2014) (391)
- Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry. (2016) (360)
- Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. (2004) (353)
- Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction: The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) Trial (2003) (346)
- The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation (2015) (343)
- Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. (2011) (337)
- Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF (2012) (335)
- Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus (2018) (334)
- A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. (2006) (321)
- Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events (2017) (308)
- Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. (2013) (307)
- Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. (2002) (294)
- Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study (2009) (292)
- 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. (2017) (286)
- Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. (2013) (286)
- 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. (2018) (285)
- Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion. (2001) (284)
- Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial (2014) (281)
- Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: The Apple Heart Study (2018) (277)
- 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials (2018) (248)
- 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). (2015) (235)
- Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial (2013) (231)
- A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes (2010) (226)
- Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. (2015) (225)
- Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. (2011) (224)
- ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use (2008) (223)
- Comparison of the ABC/2 estimation technique to computer-assisted volumetric analysis of intraparenchymal and subdural hematomas complicating the GUSTO-1 trial. (1998) (219)
- Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients With Atrial Fibrillation (2015) (219)
- Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention (1999) (218)
- Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). (2014) (215)
- Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. (2015) (212)
- Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study. (2006) (203)
- Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes (2014) (201)
- Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial (2016) (200)
- Effect of Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Fibrinolysis in Acute Myocardial Infarction: The COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) Trial (2003) (193)
- Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups (2019) (191)
- Mechanical complications after percutaneous coronary intervention in ST-elevation myocardial infarction (from APEX-AMI). (2010) (189)
- Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery. (2011) (189)
- Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function (2018) (186)
- Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation (2008) (183)
- The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics (2017) (180)
- Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial (2014) (177)
- Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From the Platelet Inhibition and Patient Outcomes Trial (2012) (176)
- Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation-Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). (2015) (175)
- Intracranial Hemorrhage Among Patients With Atrial Fibrillation Anticoagulated With Warfarin or Rivaroxaban: The Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (2014) (173)
- Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. (2007) (170)
- The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. (2003) (164)
- Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. (2014) (162)
- Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) (2015) (162)
- Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. (2007) (161)
- Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial. (2015) (161)
- Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial. (2015) (157)
- ST-Segment Recovery and Outcome After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction: Insights From the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial (2008) (156)
- International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD‐AF, ORBIT‐AF I, and ORBIT‐AF II registries (2017) (154)
- Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. (2014) (152)
- Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. (2011) (152)
- Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF (2016) (149)
- Results of a reevaluation of cardiovascular outcomes in the RECORD trial. (2013) (147)
- Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial (2014) (144)
- Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes: An Analysis From the Prospective, Randomized PLATO Trial (2013) (137)
- Frequency and Outcomes of Reduced Dose Non–Vitamin K Antagonist Anticoagulants: Results From ORBIT‐AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II) (2018) (136)
- Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial. (2018) (134)
- Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and a History of Stroke or Transient Ischemic Attack (2012) (133)
- Ticagrelor Versus Clopidogrel in Elderly Patients With Acute Coronary Syndromes: A Substudy From the Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLATO) Trial (2012) (130)
- Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial FibrillationClinical Perspective (2013) (130)
- Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation (2016) (127)
- On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF (2015) (127)
- The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. (2009) (125)
- Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. (2000) (123)
- Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (CANVAS‐R): A randomized, placebo‐controlled trial (2017) (122)
- Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal (2007) (121)
- Sodium‐Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis (2020) (120)
- 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Solution Set Oversight Committee. (2020) (120)
- Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. (2005) (119)
- Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. (2000) (118)
- Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus. (2019) (113)
- Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). (2015) (112)
- Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial (2014) (112)
- Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). (2014) (111)
- Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (2013) (108)
- Use and Associated Risks of Concomitant Aspirin Therapy With Oral Anticoagulation in Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry (2013) (106)
- Efficacy and Safety of Rivaroxaban in Patients With Heart Failure and Nonvalvular Atrial Fibrillation: Insights From ROCKET AF (2013) (106)
- Thrombolysis-related intracranial hemorrhage: a radiographic analysis of 244 cases from the GUSTO-1 trial with clinical correlation. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. (1998) (101)
- Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. (2012) (100)
- Relationship Between Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results From the ROCKET AF Trial (2014) (99)
- Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS‐R trials (2017) (99)
- Effect of Alirocumab on Mortality After Acute Coronary Syndromes (2019) (99)
- Left ventricular performance and remodeling in rabbits after myocardial infarction. Effects of a thyroid hormone analogue. (1995) (99)
- Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). (2013) (98)
- Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non–ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization: A Substudy From the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial (2014) (96)
- Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. (2011) (96)
- Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients. (2003) (94)
- Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). (2014) (93)
- Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes: ORBIT-AF Registry. (2017) (92)
- Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non‐valvular atrial fibrillation: Results from ROCKET AF (2014) (90)
- Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease (2017) (90)
- Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (2018) (89)
- Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort. (2015) (89)
- Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibi (2006) (89)
- Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. (1997) (88)
- Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. (1996) (88)
- Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. (2012) (88)
- 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials (2015) (87)
- Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Chronic Kidney Disease According to Baseline HbA1c, Including Those with HbA1c <7%: Results From the CREDENCE Trial. (2019) (86)
- Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial (2015) (85)
- Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. (2013) (83)
- Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program (2019) (83)
- Prognosis of patients taking selective serotonin reuptake inhibitors before coronary artery bypass grafting. (2006) (83)
- Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. (2014) (83)
- Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. (2020) (83)
- Risks and Benefits of Anticoagulation in Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry (2013) (82)
- Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study (2001) (82)
- Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program. (2019) (81)
- Risk factors for in-hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: results from GUSTO-I. (1998) (80)
- A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes. (2006) (79)
- Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. (2012) (79)
- Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. (1999) (79)
- Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study (2016) (78)
- Fractional Flow Reserve-Guided PCI as Compared with Coronary Bypass Surgery. (2021) (78)
- Efficacy and safety of canagliflozin when used in conjunction with incretin‐mimetic therapy in patients with type 2 diabetes (2016) (77)
- Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry. (2016) (76)
- The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. (2015) (75)
- Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes. (2020) (74)
- Lack of Concordance Between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry (2014) (74)
- Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. (2000) (74)
- Systematic adjudication of myocardial infarction end-points in an international clinical trial (2001) (70)
- High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. (2005) (69)
- Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. (2013) (67)
- Baseline Q-wave surpasses time from symptom onset as a prognostic marker in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention. (2009) (67)
- Gastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatment (2014) (67)
- Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II. (1999) (66)
- Enzyme estimates of infarct size correlate with functional and clinical outcomes in the setting of ST-segment elevation myocardial infarction (2005) (66)
- Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes - A systematic review. (2018) (66)
- Association of Myocardial Enzyme Elevation and Survival Following Coronary Artery Bypass Graft Surgery (2012) (65)
- The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial. (2013) (65)
- Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry. (2014) (65)
- Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial. (2002) (64)
- Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF (2018) (64)
- Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT. (2000) (61)
- Clinical Outcomes With Rivaroxaban in Patients Transitioned From Vitamin K Antagonist Therapy (2013) (61)
- Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV). (2008) (61)
- Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial. (2020) (60)
- Predictors and Prognostic Implications of Incident Heart Failure in Patients With Prevalent Atrial Fibrillation. (2017) (60)
- Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. (2020) (60)
- Pattern of liver enzyme elevations in acute ST-elevation myocardial infarction (2012) (59)
- Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial. (2020) (59)
- Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in HemodialysisCLINICAL PERSPECTIVE (2015) (59)
- Milvexian for the Prevention of Venous Thromboembolism. (2021) (58)
- Provider Specialty and Atrial Fibrillation Treatment Strategies in United States Community Practice: Findings From the ORBIT‐AF Registry (2013) (58)
- Time to Coronary Angiography and Outcomes Among Patients With High-Risk Non–ST-Segment–Elevation Acute Coronary Syndromes: Results From the SYNERGY Trial (2007) (57)
- Prediction of 30-day mortality among patients with thrombolysis-related intracranial hemorrhage. (1998) (57)
- Rationale and strategies for implementing community-based transfer protocols for primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. (2004) (57)
- Prevalence, predictors, and impact of conservative medical management for patients with non-ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease. (2008) (56)
- Factors associated with non–vitamin K antagonist oral anticoagulants for stroke prevention in patients with new‐onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT‐AF II) (2017) (56)
- Management of Patients With NSTE-ACS: A Comparison of the Recent AHA/ACC and ESC Guidelines. (2016) (55)
- Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). (2017) (55)
- Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial. (2016) (54)
- Defining Heart Failure End Points in ST-Segment Elevation Myocardial Infarction Trials: Integrating Past Experiences to Chart a Path Forward (2012) (53)
- Prediction of One-Year Survival in High-Risk Patients with Acute Coronary Syndromes: Results from the SYNERGY Trial (2008) (53)
- Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. (2012) (53)
- Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study (2018) (52)
- Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. (2016) (52)
- Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program (2019) (51)
- Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry (2017) (51)
- Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. (2010) (51)
- Heart failure complicating non-ST-segment elevation acute coronary syndrome: timing, predictors, and clinical outcomes. (2013) (50)
- Sharing Data from Cardiovascular Clinical Trials--A Proposal. (2016) (50)
- Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. (2014) (50)
- Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. (2016) (50)
- Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation (2019) (50)
- Abstract 148: Efficacy and Safety of Rivaroxaban Compared with Warfarin Among Elderly Patients with Nonvalvular Atrial Fibrillation in the ROCKET-AF Trial (2012) (49)
- Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes. (2020) (49)
- Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial. (2016) (49)
- Heart rate is associated with progression of atrial fibrillation, independent of rhythm (2015) (49)
- Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. (2021) (48)
- Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. (2020) (48)
- Statin Use and Sex-Specific Stroke Outcomes in Patients With Vascular Disease (2006) (48)
- Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). (2002) (48)
- Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial (2018) (47)
- Polyvascular Disease and Risk of Major Adverse Cardiovascular Events in Peripheral Artery Disease: A Secondary Analysis of the EUCLID Trial. (2018) (47)
- Prognostic implications of left ventricular end-diastolic pressure during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Findings from the Assessment of Pexelizumab in Acute Myocardial Infarction study. (2013) (47)
- Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial (2019) (46)
- Rivaroxaban, an oral direct factor Xa inhibitor. (2008) (46)
- End of Study Transition From Study Drug to Open-Label Vitamin K Antagonist Therapy: The ROCKET AF Experience (2013) (46)
- Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial. (2008) (46)
- Grade III Ischemia on Presentation with Acute Myocardial Infarction Predicts Rapid Progression of Necrosis and Less Myocardial Salvage with Thrombolysis (2002) (45)
- Outpatient Inhaled Nitric Oxide in a Patient with Vasoreactive Idiopathic Pulmonary Arterial Hypertension and COVID-19 Infection (2020) (45)
- Predictors and Prognostic Implications of Incident Heart Failure in Patients With Prevalent Atrial Fibrillation. (2016) (45)
- Association of Body Mass Index With Care and Outcomes in Patients With Atrial Fibrillation: Results From the ORBIT-AF Registry. (2016) (44)
- Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview. (2006) (44)
- Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial. (2014) (44)
- Data monitoring committees: Promoting best practices to address emerging challenges (2017) (44)
- Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial. (2002) (44)
- Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). (2014) (43)
- Canagliflozin and Stroke in Type 2 Diabetes Mellitus (2018) (43)
- Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease: The EUCLID Trial. (2018) (43)
- Standardized Definitions for Cardiovascular and Stroke Endpoint Events in Clinical Trials (2014) (42)
- Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial. (2013) (42)
- Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF) (2015) (41)
- Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends. (2013) (41)
- Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). (2014) (41)
- Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I trial. Global Utilization of Streptokinase and tissue-plasminogen activator (tPA) for Occluded Coronary Arteries. (1999) (41)
- Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF Trial. (2016) (41)
- Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes (2014) (41)
- Abstract 19281: Outcomes Following Cardioversion and Atrial Fibrillation Ablation in Patients Treated with Rivaroxaban and Warfarin in the ROCKET AF Trial (2012) (40)
- Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials (2022) (40)
- Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes. (2010) (40)
- Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial. (2005) (40)
- Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: results from the PURSUIT trial. (2001) (40)
- Cardiogenic shock and heart failure post-percutaneous coronary intervention in ST-elevation myocardial infarction: observations from "Assessment of Pexelizumab in Acute Myocardial Infarction". (2011) (40)
- Direct Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials with Interaction Testing by Age and Sex. (2022) (39)
- Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease (2021) (39)
- Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials (2017) (38)
- Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban (2016) (38)
- Acute Limb Ischemia in Peripheral Artery Disease: Insights from EUCLID. (2019) (38)
- Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial (2015) (38)
- A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trial. (2001) (38)
- Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation (2010) (38)
- Characteristics of Digital Health Studies Registered in ClinicalTrials.gov. (2019) (37)
- Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT‐AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation) (2017) (37)
- Rivaroxaban, an oral direct factor Xa inhibitor (2008) (37)
- Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction. (2020) (37)
- Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]). (2015) (37)
- Use and Associated Risks of Concomitant Aspirin Therapy with Oral Anticoagulation in Patients with Atrial Fibrillation: Insights from the ORBIT-AF Registry (2013) (36)
- Use of evidence-based cardiac prevention therapy among outpatients with atrial fibrillation. (2013) (36)
- Effect of Atrial Fibrillation on Mortality, Stroke Risk, and Quality-of-Life Scores in Patients With Heart Failure (from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF]). (2017) (36)
- Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials (2022) (35)
- Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial. (2020) (35)
- Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. (2020) (35)
- Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. (2017) (34)
- International consensus definitions of clinical trial outcomes for kidney failure: 2020. (2020) (34)
- Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes (2017) (34)
- Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction (from the CARDINAL Trial). (2005) (34)
- The Project Baseline Health Study: a step towards a broader mission to map human health (2020) (33)
- A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial (2013) (33)
- Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy. (2013) (33)
- Cardiovascular Outcomes After Lower Extremity Endovascular or Surgical Revascularization: The EUCLID Trial. (2018) (33)
- Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarction. (2006) (33)
- Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non–ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 Years (2015) (33)
- Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. (2016) (33)
- Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry. (2005) (32)
- Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials. (2006) (32)
- Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease (2021) (32)
- Racial Differences in Quality of Anticoagulation Therapy for Atrial Fibrillation (from the TREAT-AF Study). (2016) (32)
- Dedicated kidney disease‐focused outcome trials with sodium‐glucose cotransporter‐2 inhibitors: Lessons from CREDENCE and expectations from DAPA‐HF, DAPA‐CKD, and EMPA‐KIDNEY (2020) (32)
- The Systemic Inflammatory Response Syndrome in Patients With ST-Segment Elevation Myocardial Infarction* (2013) (32)
- Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis (2017) (32)
- Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial). (2017) (31)
- Resolution of ST-segment depression: A new prognostic marker in ST-segment elevation myocardial infarction. (2010) (31)
- An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome (2017) (31)
- Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]). (2017) (31)
- Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Study. (1999) (30)
- Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarction. (2012) (30)
- Comparing classifications of death in the Mode Selection Trial: agreement and disagreement among site investigators and a clinical events committee. (2006) (30)
- Rhythm Control Versus Rate Control and Clinical Outcomes in Patients With Atrial Fibrillation: Results From the ORBIT-AF Registry. (2016) (29)
- Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF (2016) (29)
- N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction. (2006) (28)
- Mortality Implications of Primary Percutaneous Coronary Intervention Treatment Delays: Insights From the Assessment of Pexelizumab in Acute Myocardial Infarction Trial (2011) (28)
- Sodium‐glucose co‐transporter‐2 inhibitors with and without metformin: A meta‐analysis of cardiovascular, kidney and mortality outcomes (2020) (28)
- Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions (2016) (28)
- Challenges and priorities for research: a report from the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH) Working Group on thrombosis in pediatric cardiology and congenital heart disease. (2014) (28)
- Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial (2021) (27)
- Incidence and Outcomes of Gastrointestinal Hemorrhage in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: Results From the ROCKET AF Trial (2012) (27)
- The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program (2019) (27)
- Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes (2014) (27)
- Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies. (2003) (27)
- Stroke in Patients With Peripheral Artery Disease. (2019) (27)
- Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program. (2020) (27)
- Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials (2015) (26)
- Baseline NT-proBNP and biomarkers of inflammation and necrosis in patients with ST-segment elevation myocardial infarction: insights from the APEX-AMI trial (2012) (26)
- Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER (2021) (26)
- Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial). (2004) (26)
- Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome. (2004) (25)
- Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial (2019) (25)
- The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX (2015) (25)
- Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome. (2016) (25)
- Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial. (2018) (25)
- ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation (2013) (24)
- Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY. (2010) (24)
- Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention. (2018) (24)
- Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial Fibrillation. (2017) (24)
- Patterns of discharge antiplatelet therapy and late outcomes among 8,582 patients with bleeding during acute coronary syndrome: a pooled analysis from PURSUIT, PARAGON-A, PARAGON-B, and SYNERGY. (2010) (24)
- Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis. (2021) (24)
- B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation (2018) (24)
- Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes. (2004) (24)
- Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis. (2017) (24)
- Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial. (2016) (23)
- Efficacy and safety of Canagliflozin (CANA), an inhibitor of Sodium Glucose Co-Transporter 2 (SGLT2), added on to insulin therapy with or without oral agents in type 2 diabetes (T2D) (2013) (23)
- Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation (2018) (23)
- Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines: Findings From ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) (2017) (23)
- Canagliflozin review – safety and efficacy profile in patients with T2DM (2019) (23)
- Does the discharge ECG provide additional prognostic insight(s) in non-ST elevation ACS patients from that acquired on admission? (2003) (23)
- Centralized adjudication of cardiovascular end points in cardiovascular and noncardiovascular pharmacologic trials: a report from the Cardiac Safety Research Consortium. (2015) (23)
- Release kinetics of circulating cardiac myosin binding protein-C following cardiac injury. (2014) (23)
- External validation of the TIMI risk score for secondary cardiovascular events among patients with recent myocardial infarction. (2018) (23)
- Baseline glucose and left ventricular remodeling after acute myocardial infarction. (2007) (23)
- Family history of atrial fibrillation is associated with earlier-onset and more symptomatic atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. (2016) (22)
- Disease understanding in patients newly diagnosed with atrial fibrillation (2017) (22)
- Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. (2013) (22)
- Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trial (2018) (22)
- Danazol Increases the Anticoagulant Effect of Warfarin (1992) (21)
- Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy (2013) (21)
- Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non–ST-Segment–Elevation Acute Coronary Syndromes Clinical Trials (2016) (21)
- Magnitude of Troponin Elevation and Long-Term Clinical Outcomes in Acute Coronary Syndrome Patients Treated With and Without Revascularization (2015) (21)
- Coronary artery bypass surgery in patients with acute coronary syndromes is difficult to predict. (2008) (21)
- Reviewing the role of healthy volunteer studies in drug development (2018) (21)
- Effects of Canagliflozin on Cardiovascular, Renal, and Safety Outcomes in Participants With Type 2 Diabetes and Chronic Kidney Disease According to History of Heart Failure: Results From the CREDENCE Trial. (2020) (20)
- Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding: Lessons From the CHAMPION PHOENIX Trial. (2016) (20)
- Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis. (2016) (20)
- Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction. (2006) (20)
- Publication or presentation of results from multicenter clinical trials: evidence from an academic medical center. (2007) (20)
- Abstract 152: Predictors of Intracranial Hemorrhage Among Anticoagulated Patients with Atrial Fibrillation: Insights from the Rivaroxaban Once-daily oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) (2012) (20)
- Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial). (2014) (20)
- Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients. (2012) (20)
- Reduction in Overall Occurrences of Ischemic Events With Vorapaxar: Results From TRACER (2014) (20)
- Prognostic implications of creatine kinase-MB measurements in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention. (2014) (19)
- North American Thrombosis Forum, AF Action Initiative Consensus Document. (2016) (19)
- Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF I) Registry (2016) (19)
- Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome (2017) (19)
- Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials. (2007) (19)
- Meta-Analysis of Intracranial Hemorrhage in Acute Coronary Syndromes: Incidence, Predictors, and Clinical Outcomes (2015) (19)
- Long-term outcomes associated with hospital acquired thrombocytopenia among patients with non-ST-segment elevation acute coronary syndrome. (2014) (19)
- Electrocardiographic infarct size assessment after thrombolysis: insights from the Acute Myocardial Infarction STudy ADenosine (AMISTAD) trial. (2005) (18)
- Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial). (2015) (18)
- Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). (2014) (18)
- The future of cardiovascular clinical research in North America and beyond-addressing challenges and leveraging opportunities through unique academic and grassroots collaborations. (2015) (18)
- Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. (2014) (18)
- Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial (2016) (18)
- USE AND OUTCOMES OF ANTIARRHYTHMIC THERAPY IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING ORAL ANTICOAGULATION: RESULTS FROM THE ROCKET AF TRIAL (2014) (18)
- Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation. (2019) (18)
- Cardioversion and subsequent quality of life and natural history of atrial fibrillation (2017) (17)
- Assessing the treatment effect in a randomized controlled trial with extensive non‐adherence: the EVOLVE trial (2015) (17)
- Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: A subgroup analysis from the SYNERGY trial (2010) (17)
- Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation (2018) (17)
- Prognostic significance of bleeding location and severity among patients with acute coronary syndromes. (2013) (17)
- Cytokines profile in hypertensive patients with left ventricular remodeling and dysfunction. (2015) (17)
- Racial differences among high-risk patients presenting with non-ST-segment elevation acute coronary syndromes (results from the SYNERGY trial). (2007) (17)
- Thrombosis in Pediatric Cardiology and Congenital Heart Disease Blood Institute (NHLBI)/National Institutes of Health (NIH) Working Group on Challenges and Priorities for Research: A Report From the National Heart, Lung, and (2014) (17)
- Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillation. (2020) (17)
- The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial (2020) (17)
- Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention (2016) (16)
- Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levels. (2003) (16)
- Myocardial Infarction Adenosine as an Adjunct to Thrombolytic Therapy for Acute Myocardial Infarction (1999) (16)
- A Cluster Analysis of the Japanese Multicenter Outpatient Registry of Patients With Atrial Fibrillation. (2019) (16)
- Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition) (2018) (16)
- Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials (2019) (16)
- Sex-Specific Risks of Major Cardiovascular and Limb Events in Patients With Symptomatic Peripheral Artery Disease. (2020) (16)
- Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT‐AF (2018) (16)
- Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial (2015) (16)
- Low-molecular-weight heparin compared with unfractionated heparin for patients with non–ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: Results from the CRUSADE initiative (2006) (15)
- The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program. (2020) (15)
- Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial (2018) (15)
- Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial (2012) (15)
- Consensus Documents American College of Cardiology Foundation Task Force on Clinical Expert Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the (2008) (15)
- High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction. (2014) (15)
- Post-intervention cardiac enzyme elevations: Prognostic significance in IMPACT II (1996) (15)
- Utilization of catheterization and revascularization procedures in patients with non‐ST segment elevation acute coronary syndrome over the last decade (2005) (15)
- Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial (2015) (15)
- Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial. (2011) (14)
- Clopidogrel and PPI Interaction: Clinically Relevant or Not? (2012) (14)
- International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post‐MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee (2018) (14)
- Response to Letter Regarding Article, “Association of Proton Pump Inhibitor Use on Cardiovascular Outcomes With Clopidogrel and Ticagrelor: Insights From PLATO” (2012) (14)
- Optimal timing for use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: questions, answers, and more questions. (2007) (14)
- Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trial. (2017) (14)
- Appropriateness of Direct Oral Anticoagulant Dosing in Patients With Atrial Fibrillation: Insights From the Veterans Health Administration (2020) (13)
- Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis: Results From the TRACER Angiographic Substudy (2016) (13)
- The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial (2016) (13)
- Independent data monitoring committees: preparing a path for the future. (2014) (13)
- TICAGRELOR VERSUS CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROMES UNDERGOING CORONARY ARTERY BY-PASS SURGERY: RESULTS FROM THE PLATO TRIAL (2010) (13)
- Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial. (2016) (13)
- Abstract 15544: Rivaroxaban Compared with Warfarin in Patients with Atrial Fibrillation and Diabetes: A Subgroup Analysis of the ROCKET AF Trial (2012) (13)
- Promises of PAR-1 Inhibition in Acute Coronary Syndrome (2012) (13)
- Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial (2016) (12)
- Comparison of Clinical Trial Outcome Patterns in Patients Following Acute Coronary Syndromes and in Patients With Chronic Stable Atherosclerosis (2014) (12)
- Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). (2017) (12)
- Challenges and Solutions to Pre- and Post-Randomization Subgroup Analyses (2014) (12)
- Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial (2019) (12)
- Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials. (2018) (12)
- How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). (2016) (12)
- Embolic and Other Adverse Outcomes in Symptomatic Versus Asymptomatic Patients With Atrial Fibrillation (from the ORBIT-AF Registry). (2018) (12)
- Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial. (2007) (12)
- Temporal changes in biomarkers and their relationships to reperfusion and to clinical outcomes among patients with ST segment elevation myocardial infarction (2016) (12)
- Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. (2011) (12)
- Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX). (2017) (12)
- Arrhythmias Other Than Atrial Fibrillation in Those With an Irregular Pulse Detected With a Smartwatch (2021) (12)
- Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years. (2013) (12)
- Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrel (2014) (12)
- Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial (2018) (12)
- Determinants of plasma vitamin D levels in patients with acute coronary syndromes (2011) (11)
- Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program. (2020) (11)
- Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials. (2018) (11)
- Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study (2017) (11)
- Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program (2021) (11)
- Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin. (2022) (11)
- Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial (2018) (11)
- Shared Decision Making in Atrial Fibrillation: Patient-Reported Involvement in Treatment Decisions. (2020) (11)
- A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes. (2005) (11)
- Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndrome. (2008) (11)
- Platelet glycoprotein IIb/IIIa receptor antagonists in non-ST segment elevation acute coronary syndromes: a review and guide to patient selection. (2005) (11)
- Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy. (2008) (11)
- Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program (2019) (11)
- Incremental value of diastolic stress test in identifying subclinical heart failure in patients with diabetes mellitus. (2020) (10)
- Integrating ancillary studies in a large clinical trial: the design and rationale of the APEX library. (2008) (10)
- Comparison of Patient‐Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT‐AF Registry (2019) (10)
- Results of a curtailed randomized controlled trial, evaluating the efficacy and safety of azimilide in patients with implantable cardioverter‐defibrillators: The SHIELD‐2 trial (2017) (10)
- Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF. (2018) (10)
- Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS Program and CREDENCE trial. (2021) (10)
- Prognostic utility of quantifying evolutionary ST-segment depression on early follow-up electrocardiogram in patients with non-ST-segment elevation acute coronary syndromes. (2010) (10)
- Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the ORBIT-AF Registry). (2019) (10)
- Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation (2020) (10)
- Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation (2017) (10)
- Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes (2016) (10)
- Preventing Atrial Fibrillation With Treatments for Diabetes Mellitus. (2020) (10)
- Initial risk stratification and presenting characteristics of patients with evolving myocardial infarctions (2008) (10)
- Efficacy and Safety of Vorapaxar in Non–ST‐Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery (2015) (10)
- Cohort profile: patient characteristics and quality-of-life measurements for newly-referred patients with atrial fibrillation—Keio interhospital Cardiovascular Studies-atrial fibrillation (KiCS-AF) (2019) (10)
- Cardiac enzyme elevations after cardiac surgery: the cardiologist's perspective. (2001) (9)
- Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease (2021) (9)
- TRADEOFF BETWEEN MYOCARDIAL INFARCTION VERSUS BLEEDING TYPES ON MORTALITY AFTER ACUTE CORONARY SYNDROME: LESSONS FROM THE THROMBIN RECEPTOR ANTAGONIST FOR CLINICAL EVENT REDUCTION IN ACUTE CORONARY SYNDROME (TRACER) RANDOMIZED TRIAL (2016) (9)
- Navigating the Future of Cardiovascular Drug Development—Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference (2017) (9)
- Dynamic modeling of 90-day mortality in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention. (2013) (9)
- Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. (2019) (9)
- Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites. (2017) (9)
- Management of acute coronary syndromes in patients with renal dysfunction (2008) (9)
- Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). (2020) (9)
- Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary Intervention. (2019) (9)
- Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry (2018) (9)
- Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial (2022) (8)
- Therapeutic Strategies Following Major, Clinically Relevant Nonmajor, and Nuisance Bleeding in Atrial Fibrillation: Findings From ORBIT‐AF (2018) (8)
- Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial. (2018) (8)
- Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. (2019) (8)
- The scientific community's quest to identify optimal targets for anticoagulant pharmacotherapy. (2006) (8)
- Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience (2018) (8)
- Cinacalcet, FGF23 and Cardiovascular Disease in Hemodialysis: The EVOLVE Trial (2015) (8)
- Abstract 12092: Proton Pump Inhibitor Use is Likely a Marker for, Rather than a Cause of, a Higher Risk of Cardiovascular Events: Insights from PLATO (2010) (8)
- Disagreement between site investigators and clinical event committees is common and can affect trial results (1998) (8)
- Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials. (2019) (8)
- Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention (2017) (8)
- Incorporation of bleeding as an element of the composite end point in clinical trials of antithrombotic therapies in patients with non-ST-segment elevation acute coronary syndrome: validity, pitfalls, and future approaches. (2013) (8)
- Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome (2018) (8)
- Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA2DS2‐VASc Scores: Findings From the ORBIT‐AF I and II Registries (2018) (8)
- Association Between Circulating GDF‐15 and Cardio‐Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial (2021) (8)
- Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library. (2004) (8)
- The Efficacy and Safety of Cangrelor in Women Versus Men During PCI: Insights From the CHAMPION PHOENIX Trial (2016) (8)
- Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation. (2019) (7)
- The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale and design (2018) (7)
- Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar (2016) (7)
- Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial (2016) (7)
- Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist (2022) (7)
- Mineralocorticoid Receptor Antagonism in Patients With Atrial Fibrillation: Findings From the ORBIT‐AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) Registry (2018) (7)
- Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study. (2020) (7)
- CANAGLIFLOZIN (CANA) REDUCES CARDIOVASCULAR (CV) AND RENAL EVENTS INDEPENDENT OF BASELINE HEART FAILURE (HF): A CREDENCE SECONDARY ANALYSIS (2020) (7)
- Anticoagulation for acute coronary syndromes and percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (2001) (7)
- Lost to Follow-up and Withdrawal of Consent in Contemporary Global Cardiovascular Randomized Clinical Trials. (2015) (7)
- Assessing the treatment effect in a randomized controlled trial with extensive non‐adherence: the EVOLVE trial (2015) (7)
- Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: The EUCLID trial (2019) (7)
- Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome (2011) (7)
- Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial (2022) (7)
- Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention: Findings From CHAMPION PHOENIX (2017) (7)
- Incremental prognostic value of renal function for stroke prediction in atrial fibrillation. (2019) (7)
- Mode of death and hospitalization from the Second Follow-up Serial Infusions of Nesiritide (FUSION II) trial and comparison of clinical events committee adjudicated versus investigator reported outcomes. (2011) (7)
- Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. (2016) (6)
- Cause of Death Among Patients With Peripheral Artery Disease (2020) (6)
- Return of individual research results: What do participants prefer and expect? (2021) (6)
- Impact of Procedural Bleeding in Peripheral Artery Disease: An Analysis From EUCLID Trial. (2019) (6)
- The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial (2020) (6)
- Abstract 16842: Obstructive Hypertrophic Cardiomyopathy: Initial Single Ascending Dose Data in Healthy Volunteers and Patients (2016) (6)
- Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention. (2019) (6)
- An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials. (2020) (6)
- Impact of enoxaparin on thrombus formation, coronary blood flow, and myocardial perfusion after early invasive treatment during acute coronary syndrome: Results from the SYNERGY library (2006) (6)
- Association of Hypertension and Arterial Blood Pressure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery Disease (2020) (6)
- Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis (2018) (6)
- Abstract 19049: Net Clinical Benefit of Vorapaxar in NSTE ACS: Role of Ischemic and Bleeding Risk Stratification (2012) (6)
- Eligibility of sodium–glucose co‐transporter‐2 inhibitors among patients with diabetes mellitus admitted for heart failure (2019) (6)
- The Project Baseline Health Study: a step towards a broader mission to map human health. (2020) (6)
- 833-5 Markers of inflammation predict mortality and are reduced by pexelizumab in patients with acute myocardial infarction: Insights from the complement inhibition in myocardial infarction treated with angioplasty (COMMA) trial (2004) (6)
- Association of Heart Failure With Outcomes Among Patients With Peripheral Artery Disease: Insights From EUCLID (2021) (6)
- Abstract 13482: Ischemic Cardiac Outcomes in Patients with AF Treated with Vitamin K Antagonism or Factor Xa Inhibition: Results from the ROCKET AF Trial (2011) (6)
- Sinus Node Dysfunction Is Associated With Higher Symptom Burden and Increased Comorbid Illness: Results From the ORBIT‐AF Registry (2015) (6)
- A Call for a New Paradigm for Diabetes Care in the Era of Sodium–Glucose Cotransporter 2 Inhibitors (SGLT2i) (2020) (6)
- Abstract #259 Cardiovascular and Renal Outcomes with Canagliflozin in People with Type 2 Diabetes According to Baseline use of Metformin (2019) (6)
- Influence of body mass index on the efficacy of revascularization in patients with coronary artery disease. (2009) (6)
- Vorapaxar: emerging evidence and clinical questions in a new era of PAR-1 inhibition (2016) (6)
- Efficacy and Safety of Canaglif lozin, an Inhibitor of Sodium Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes (2014) (6)
- Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial (2021) (6)
- A 15-year review of the Stanford Internal Medicine Residency Program: predictors of resident satisfaction and dissatisfaction (2017) (5)
- Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF (2018) (5)
- Adjuvant Antithrombotic Therapy in TAVR (2017) (5)
- "Off-Hours" Versus "On-Hours" Presentation in ST-Segment Elevation Myocardial Infarction: CHAMPION PHOENIX Findings. (2016) (5)
- The ODYSSEY OUTCOMES Trial (2019) (5)
- Why digital health trials can fail: Lessons learned from a randomized trial of health coaching and virtual cardiac rehabilitation (2021) (5)
- Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes. (2004) (5)
- Incidence and Factors Associated With Major Amputation in Patients With Peripheral Artery Disease (2020) (5)
- Risk Factors for In-hospital Nonhemorrhagic Stroke in Patients With Acute Myocardial Infarction Treated With Thrombolysis: Results from GUSTO-I : Results From Gusto-I (1998) (5)
- Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial (2022) (5)
- Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial (2016) (5)
- THROMBOLYTIC THERAPY IN ANTICOAGULATED PATIENTS: CASE SERIES FROM RIVAROXABAN VERSUS WARFARIN IN NONVALVULAR ATRIAL FIBRILLATION (ROCKET AF) (2017) (5)
- Abstract 9150: Re-Elevation of Troponin Following Percutaneous Coronary Intervention Significantly Predicts 1-Year Mortality in Patients with High-risk Non-ST-Segment Elevation Acute Coronary Syndromes (2011) (5)
- Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial. (2019) (5)
- Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials. (2018) (5)
- Major bleeding in patients with peripheral artery disease: Insights from the EUCLID trial. (2019) (5)
- Discharge timing and outcomes after uncomplicated non–ST‐segment elevation acute myocardial infarction (2018) (5)
- Background and Proposed Design for a Metformin Abdominal Aortic Aneurysm Suppression Trial (2020) (5)
- Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial (2022) (5)
- Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin (2012) (4)
- The Impact of Postrandomization Crossover of Therapy in Acute Coronary Syndromes Care (2011) (4)
- Abstract 14365: Rivaroxaban is Associated with a Reduced Risk of Thromboembolic events and Hemorrhagic Stroke in Patient with Heart Failure: Insights from ROCKET AF (2012) (4)
- OBSTRUCTIVE SLEEP APNEA AND ATRIAL FIBRILLATION: FINDINGS FROM ORBIT-AF (2014) (4)
- Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program (2021) (4)
- Prediction of enzymatic infarct size in ST-segment elevation myocardial infarction (2012) (4)
- The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX (2019) (4)
- Abstract 16889: Digoxin Use and Subsequent Outcomes Among Patients with and without Heart Failure in a Contemporary Atrial Fibrillation Cohort: Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) (2014) (4)
- Abstract 15686: Polypharmacy and the Efficacy and Safety of Rivaroxaban versus Warfarin in the Prevention of Stroke: Results From the ROCKET AF Trial (2014) (4)
- Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14–16, 2010, São Paulo, Brazil (2010) (4)
- The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. (2023) (4)
- Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromes. (2003) (4)
- Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. (2019) (4)
- Edinburgh Research Explorer Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation (2015) (4)
- Outcomes of patients with atrial fibrillation and significant valvular lesions: Comparison of the effects of rivaroxaban and warfarin in the ROCKET AF trial (2013) (4)
- CANGRELOR IN ELDERLY PATIENTS UNDERGOING PCI: FINDINGS FROM CHAMPION-PHOENIX (2015) (4)
- FP482EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER (2019) (4)
- EFFECTS OF CANAGLIFLOZIN ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES BY BASELINE LOOP DIURETIC USE: DATA FROM THE CREDENCE TRIAL (2020) (4)
- ESC Guidelines on the management of acute myocardial infarction with persistent ST-segment elevation (2012) (4)
- Association of Health Status Scores With Cardiovascular and Limb Outcomes in Patients With Symptomatic Peripheral Artery Disease: Insights From the EUCLID (Examining Use of Ticagrelor in Symptomatic Peripheral Artery Disease) Trial (2020) (4)
- Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling. (2016) (4)
- Efficacy of a Centralized, Blended Electronic and Human Intervention to Improve Direct Oral Anticoagulant Adherence: Smartphones to improve rivaroxaban ADHEREnce in Atrial Fibrillation (SmartADHERE) A Randomized Clinical Trial: SmartADHERE rivaroxaban adherence trial. (2021) (4)
- Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF (2019) (4)
- MAJOR BLEEDING IN PATIENTS WITH PERIPHERAL ARTERY DISEASE: INSIGHTS FROM THE EUCLID TRIAL (2018) (4)
- FP483EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) – A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER (2019) (4)
- Canagliflozin and Renal Outcomes in Diabetic Nephropathy. Reply. (2019) (4)
- Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes. (2005) (4)
- Does the Discharge ECG Provide Additional Prognostic Insight(s) from That Acquired on Admission (2001) (4)
- Pooled analysis of adverse event collection from 4 acute coronary syndrome trials. (2016) (3)
- Cardiovascular adverse events in the drug‐development program of bupropion for smoking cessation: A systematic retrospective adjudication effort (2017) (3)
- TCT-79 Efficacy of Cangrelor in Lesions with High-Risk and Low-Risk Angiographic Characteristics: The CHAMPION PHOENIX trial (2015) (3)
- SUBSTANTIAL VARIABILITY BETWEEN LABORATORIES IN TROPONIN DECISION LEVEL FOR DIAGNOSIS OF MYOCARDIAL INFARCTION AND ASSAY 99TH PERCENTILE: FINDINGS FROM THE INTERNATIONAL STUDY OF COMPARATIVE HEALTH EFFECTIVENESS WITH MEDICAL AND INVASIVE APPROACHES (ISCHEMIA) TRIAL (2014) (3)
- THE EFFICACY, SAFETY, AND NET CLINICAL BENEFIT OF CANGRELOR IN WOMEN UNDERGOING ELECTIVE OR URGENT PCI: INSIGHTS FROM THE CHAMPION-PHOENIX TRIAL (2015) (3)
- Response to letter regarding article, "Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial". (2014) (3)
- Fasting Substrate Concentrations Predict Cardiovascular Outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS). (2022) (3)
- Relation of Post-Coronary Artery Bypass Graft Creatine Kinase-MB Elevations and New Q Waves With Long-Term Cardiovascular Death in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease. (2016) (3)
- Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective (2021) (3)
- Have Angiographically Documented Significant Coronary Disease Patients With NonST-Segment Elevation Acute Coronary Syndromes Who Prevalence, Predictors, and Impact of Conservative Medical Management for (2011) (3)
- Clinical Events Classification (CEC) in Clinical Trials: Report on the Current Landscape and Future Directions - Proceedings from the CEC Summit 2018. (2021) (3)
- 1118-101 Congestive Heart Failure and Cardiogenic Shock Complicating Acute Myocardial Infarction Have High Mortality and Are Associated With Intense Inflammatory Response: Results From the CARDINAL Trials (2004) (3)
- Promise of Factor Xa Inhibition in Atrial Fibrillation (2012) (3)
- Rivaroxaban versus Warfarin in Patients with Atrial Fibrillation Enrolled in Latin America: Insights from ROCKET AF. (2021) (3)
- Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis (2021) (3)
- RACIAL/ETHNIC DIFFERENCES IN ATRIAL FIBRILLATION SYMPTOMS, TREATMENT PATTERNS, AND OUTCOMES: INSIGHTS FROM OUTCOMES REGISTRY FOR BETTER INFORMED TREATMENT FOR ATRIAL FIBRILLATION (ORBIT-AF) REGISTRY (2015) (3)
- Lack of concordance between angiographic core laboratory and CEC in the assessment of stent thrombosis: results from the TRACER angiographic substudy (2013) (3)
- MANAGEMENT AND OUTCOMES OF PATIENTS WITH ATRIAL FIBRILLATION AND CANCER: THE ORBIT-AF REGISTRY (2016) (3)
- Association of Disease Progression With Cardiovascular and Limb Outcomes in Patients With Peripheral Artery Disease (2020) (3)
- Cangrelor in clinical use. (2020) (3)
- TICAGRELOR VERSUS CLOPIDOGREL IN WOMEN WITH ACUTE CORONARY SYNDROMES – A SUBSTUDY FROM THE PROSPECTIVE RANDOMIZED PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL (2012) (3)
- The use of tomographic myocardial perfusion scanning to evaluate an electrocardiographic salvage estimation method in patients with acute myocardial infarction: an AMISTAD substudy. Acute Myocardial Infarction Study Adenosine. (1999) (3)
- Abstract 12191: Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Non-Cardiac Surgery (2014) (3)
- Association of Healthcare Plan with atrial fibrillation prescription patterns (2018) (3)
- Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta‐analysis (2022) (3)
- The evaluation and management of dyslipidemia and impaired glucose metabolism during acute coronary syndromes (2004) (3)
- Multi-dimensional characterization of prediabetes in the Project Baseline Health Study (2022) (3)
- Comparison of stroke rates in patients with acute coronary syndromes and patients with acute myocardial infarction (1998) (3)
- Abstract 15879: Management of Major Bleeding Events in Patients Treated With Rivaroxaban Versus Warfarin: Results From the ROCKET AF Trial (2013) (3)
- Patterns of oral anticoagulation use with cardioversion in clinical practice (2020) (3)
- Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease (2022) (3)
- A Curated Web Tracker of Global Development of Treatments and Vaccines for COVID-19 (2020) (3)
- ISCHEMIC EVENTS OCCUR EARLY IN PATIENTS UNDERGOING PCI AND ARE REDUCED WITH CANGRELOR: FINDINGS FROM CHAMPION PHOENIX (2017) (3)
- THE MYTH OF THE STABLE INR PATIENT: RESULTS FROM ORBIT-AF (2015) (3)
- OBESITY PARADOX FOR STROKE IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH RIVAROXABAN AND WARFARIN IN THE ROCKET AF TRIAL (2014) (3)
- Platelet Glycoprotein IIb/IIIa Receptor Antagonists in Non-ST Segment Elevation Acute Coronary Syndromes (2012) (3)
- Abstract 14299: Cardiovascular Events in Acute Coronary Syndrome Patients With Peripheral Arterial Disease Treated With Ticagrelor Compared to Clopidogrel: Data From the PLATO Trial (2011) (3)
- Abstract 10045: A Novel Approach to Define Type 4a Myocardial Infarction in Acute Coronary Syndrome Patients Undergoing Early Invasive Management: Insights From the CHAMPION PLATFORM Trial (2011) (3)
- EFFECTS OF GLYCOPROTEIN IIB/IIIA INHIBITORS IN COMBINATION WITH VORAPAXAR, A PLATELET THROMBIN-RECEPTOR ANTAGONIST, AMONG PATIENTS WITH NON-ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROMES: INSIGHTS FROM THE TRACER TRIAL (2013) (3)
- Comparison of site-reported and core laboratory-reported creatine kinase-MB values in non-ST-segment elevation acute coronary syndrome (from the international trial SYNERGY). (2009) (3)
- Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials (2021) (3)
- Association of left ventricular diastolic function with coronary artery calcium score: A Project Baseline Health Study. (2022) (3)
- Methods for safety and endpoint ascertainment: identification of adverse events through scrutiny of negatively adjudicated events (2020) (3)
- Polyvascular Disease and Risk ofMajor Adverse Cardiovascular Events in Peripheral Artery Disease (2018) (2)
- Abstract 18805: Vorapaxar, A Platelet Thrombin-Receptor Antagonist, in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Results from the TRACER Trial (2012) (2)
- EFFECTS OF CANAGLIFLOZIN ON STROKE IN THE CREDENCE TRIAL (2020) (2)
- Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program (2020) (2)
- Influence of Clinical Trial Participation on Subsequent Antithrombin Use (2010) (2)
- Etiology and Outcomes of Amputation in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial. (2021) (2)
- OUTCOMES OF TEMPORARY INTERRUPTIONS OF RIVAROXABAN OR WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION IN THE ROCKET AF TRIAL (2013) (2)
- Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients With Peripheral Artery Disease : Results From TRACER (2013) (2)
- Ef fi cacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention The CHAMPION PHOENIX (2)
- DOES FRAILTY ALTER THE BENEFITS OF ORAL ANTICOAGULATION IN PATIENTS WITH ATRIAL FIBRILLATION (2017) (2)
- SaO010EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES – A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS (2019) (2)
- CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH ATRIAL FIBRILLATION AND SIGNIFICANT VALVULAR LESIONS: EXPERIENCE FROM THE ROCKET AF TRIAL (2013) (2)
- A double-blind, randomized, placebo-controlled pilot trial to evaluate safety and efficacy of vorapaxar on arteriovenous fistula maturation (2019) (2)
- Pandemic-proof recruitment and engagement in a fully decentralized trial in atrial fibrillation patients (DeTAP) (2022) (2)
- Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II) (2021) (2)
- ORAL ANTICOAGULANT SELECTION IN COMMUNITY PATIENTS WITH NEW-ONSET ATRIAL FIBRILLATION: RESULTS FROM THE ORBIT-AF II REGISTRY (2016) (2)
- Canagliflozin and cardiovascular outcomes in Type 2 diabetes. (2020) (2)
- P73 Comparison of investigator and central events review of myocardial infarction rates as a means to improve events classification: Results from GUSTO-IIa (1996) (2)
- Initiating anticoagulation with the intention of cardioverting: does drug choice matter? (2018) (2)
- CYP2C19 Polymorphism and PON-1 Activity in NSTE ACS : Vorapaxar Effect in Relation to Clopidogrel Metabolism in the TRACER Trial (2013) (2)
- Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation (2020) (2)
- Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial (2013) (2)
- Abstract 16415: Patterns of Atrial Fibrillation and Treatment Strategies Vary According to Provider Specialty Across Community Practice Settings: Findings From the ORBIT-AF Registry (2011) (2)
- Optimal dosing of a glycoprotein IIb/IIIa antagonist with simplified renal-based algorithm: pharmacodynamic and clinical findings from PARAGON B (2001) (2)
- Abstract WP403: Factors Associated With Patient-Reported Shared Decision-Making for Stroke Prevention in Atrial Fibrillation (2019) (2)
- Anticoagulant and antiplatelet therapy choices for patients with atrial fibrillation one year after coronary stenting or acute coronary syndrome (2018) (2)
- P935Effect of hypertension and systolic blood pressure on cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: the EUCLID trial (2019) (2)
- Centralized systematic adjudication of clinical endpoints in multicenter trials of acute coronary syndromes identifies patients at high risk for adverse clinical outcomes (1996) (2)
- Abstract 14: Clinical Characteristics and Treatment Patterns of Medicaid Patients with Atrial Fibrillation: Insights From the ORBIT-AF I Registry (2015) (2)
- The ENHANCE-AF Clinical Trial to Evaluate an Atrial Fibrillation Shared Decision-Making Pathway: Rationale and Study Design. (2022) (2)
- Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial (2017) (2)
- Lessons learned in the Apple Heart Study and implications for the data management of future digital clinical trials (2022) (2)
- Improvements in Blood Pressure (BP) and Markers of Arterial Stiffness with Canagliflozin (CANA) in the CANagliflozin CardioVascular Assessment Study (CANVAS) Program (2018) (2)
- Biomarker-Based Prediction of Recurrent Ischemic Events in Patients With Acute Coronary Syndromes. (2022) (2)
- Left bundle branch block in non-ST-segment elevation acute coronary syndromes. Incidence, angiographic characteristics, and clinical outcomes. (2013) (2)
- A47 Differences in endpoint identification by investigators versus independent review (1996) (2)
- Cangrelor reduces the risk of ischemic complications in patients with single‐vessel and multi‐vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial (2017) (2)
- Diabetes and heart failure post-acute myocardial infarction: Important associations and need for evidence-based interventions (2020) (2)
- Safety of adjunctive glycoprotein IIb/IIIa blockade during rescue/early percutaneous coronary intervention following full-dose fibrinolytic therapy for acute myocardial infarction (2003) (2)
- The ARREST Pneumonia (Arrest Respiratory Failure due to Pneumonia) Trial: Rationale and Design. (2021) (1)
- Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria. (2022) (1)
- Abstract 9904: Trends in Enrollment, Patient Characteristics, Treatments and Outcomes of Older Adults With Non-ST-segment Elevation Acute Coronary Syndromes (ACS) in Clinical Trials (2013) (1)
- Stroke in Patients With Acute Coronary Syndromes Incidence and Outcomes in the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Clinical Investigation and Reports (1999) (1)
- Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AF (2021) (1)
- EFFECTS OF CANAGLIFLOZIN ON HEART FAILURE OUTCOMES WITH AND WITHOUT PRESERVED EJECTION FRACTION IN TYPE 2 DIABETES: RESULTS FROM THE CANVAS PROGRAM (2019) (1)
- Abstract 18832: The ORBIT-AF Bleeding Score: a Simple Score to Assess Major Bleeding Risk in Atrial Fibrillation (2014) (1)
- Abstract 15029: Ticagrelor Versus Clopidogrel in Patients with Acute Coronary Syndromes and History of Stroke or Transient Ischemic Accident: Results from the Platelet Inhibition and Patient Outcomes Trial (2011) (1)
- Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y12 Inhibitor Pretreatment: Analysis From the CHAMPION PHOENIX Trial (2019) (1)
- Pharmacokinetics of apixaban in patients with end stage renal disease on hemodialysis and atrial fibrillation: results from the RENAL-AF trial (2020) (1)
- The impact of canagliflozin on the risk of neuropathy events: a post-hoc exploratory analysis of the CREDENCE trial. (2022) (1)
- World regional differences in outcomes for patients with peripheral artery disease: Insights from the EUCLID trial (2021) (1)
- Late-breaking Basic Science Abstracts from the American Heart Association's Scientific Sessions 2012 2012 Late-breaking Basic Science Abstracts Late-breaking Basic Science Oral Session 22925 Cardiac Myosin Binding Protein C Is an Ultra-early and Cardiac-specific Biomarker of Myocardial Necrosis Repl (2012) (1)
- REDUCED DEATH, MYOCARDIAL INFARCTION, AND EARLY STENT THROMBOSIS WITH CANGRELOR VERSUS CLOPIDOGREL ON A BACKGROUND OF BIVALIRUDIN: INSIGHTS FROM CHAMPION PHOENIX (2014) (1)
- Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), october 18–19, 2012, Belo Horizonte, Minas Gerais, Brazil (2013) (1)
- Independence of Clinical Events Committees: A Consensus Statement from Clinical Research Organizations. (2022) (1)
- Ischaemic Events and Stent Thrombosis following Planned Discontinuation of Study Treatment with Ticagrelor or Clopidogrel in the PLATO Study (2018) (1)
- Cardiac Safety Research Consortium (CSRC) (2015) (1)
- A Post Hoc Analysis of KidneyIntelX and Cardiorenal Outcomes in Diabetic Kidney Disease. (2022) (1)
- Randomized Clinical Trial to Evaluate an Atrial Fibrillation Stroke Prevention Shared Decision‐Making Pathway (2022) (1)
- THE USE OF DUAL ANTIPLATELET THERAPY AND PATIENT OUTCOMES IN THOSE UNDERGOING PCI IN THE ROCKET AF TRIAL (2014) (1)
- Abstract 141: Outcomes Associated with Temporarily Interrupting Anticoagulation in Outpatients with Atrial Fibrillation: Results from ORBIT-AF (2014) (1)
- CANGRELOR VERSUS CLOPIDOGREL ON A BACKGROUND OF UNFRACTIONATED HEPARIN – INSIGHTS FROM CHAMPION PHOENIX (2017) (1)
- Consistent Outcomes with Canagliflozin (CANA) in Patients with Type 2 Diabetes across Geographic Regions—Results from the CANagliflozin CardioVascular Assessment Study (CANVAS) Program (2018) (1)
- Bleeding among Patients with Acute Coronary Syndromes is associated with higher risk of short- and long-term Death (2004) (1)
- SAT-156 RENAL, CARDIOVASCULAR, AND SAFETY OUTCOMES OF CANAGLIFLOZIN ACCORDING TO BASELINE ALBUMINURIA: A CREDENCE SECONDARY ANALYSIS (2020) (1)
- Experience with glycoprotein IIb/IIIa antagonists in patients with acute coronary syndromes. (2002) (1)
- Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in Practice (2020) (1)
- Abstract Seventeenth annual meeting of the society for clinical trialP29 Prognostic significance of cardiac enzyme elevations detected through systematic screening in clinical trials (1996) (1)
- Efficacy and Safety of Vorapaxar in Elderly Patients With Non-ST-Segment Elevation Acute Coronary Syndrome : Insights From the TRACER Trial (2013) (1)
- Academic health centers: integration of clinical research with healthcare and education. Comments on a workshop (2018) (1)
- Effects of canagliflozin on cardiovascular death and hospitalization for heart failure by baseline estimated glomerular filtration rate: integrated analyses from the CANVAS Program and CREDENCE (2020) (1)
- CYP2C19 status and risk of major adverse cardiovascular events in peripheral artery disease: Insights from the EUCLID Trial. (2020) (1)
- REDUCTION OF TYPE 1 AND TYPE 2 MYOCARDIAL INFARCTIONS IN PATIENTS TREATED WITH ALIROCUMAB: INSIGHTS FROM THE ODYSSEY TRIAL (2019) (1)
- Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX (2021) (1)
- 185-OR: Longitudinal Changes in KidneyIntelX and Association with Progressive Decline in Kidney Function in the CANVAS Trial (2021) (1)
- Abstract 16840: Predictors of Hospitalization in Patients With Atrial Fibrillation: An Analysis From ROCKET AF (2014) (1)
- Independent Predictors of Mortality in Patients with Nonvalvular Atrial Fibrillation: Results from ROCKET AF (2012) (1)
- Canagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program (2021) (1)
- The ARREST Pneumonia Clinical Trial. Rationale and Design (2021) (1)
- Predictors of one-year mortality in high-risk patients with acute coronary syndromes: the SYNERGY trial one-year results (2006) (1)
- TCT-75 Cangrelor Improves Ischemic Outcomes In Patients With Multivessel Disease And Single Vessel Disease Undergoing PCI: Insights From The CHAMPION PHOENIX Trial (2015) (1)
- 129-LB: Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex in the CREDENCE Trial (2021) (1)
- Intracranial hemorrhage in acute coronary syndrome: incidence, predictors, and outcomes from APPRAISE-2, PLATO, and TRACER (2013) (1)
- Inhibition and Patient Outcomes (PLATO) Trial In-Hospital Revascularization: A Substudy From the Prospective Randomized Platelet ST-Elevation Acute Coronary Syndrome Patients Managed With or Without − Non Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in (2014) (1)
- ONE-YEAR MORTALITY INCREASED IN PATIENTS WITH PERI-PROCEDURAL MYOCARDIAL INFARCTION: INSIGHTS FROM THE CHAMPION TRIALS (2017) (1)
- TCT-482 Effect of Cangrelor on Ischemic Endpoints: Further Analyses from CHAMPION PHOENIX (2014) (1)
- The ARREST Pneumonia Clinical Trial. Rationale and Design (2021) (1)
- Cardiovascular Risk Factors and Secondary Events Among Acute and Chronic Stable Myocardial Infarction Patients: Findings from a Managed Care Database (2019) (1)
- Effects of canagliflozin on major adverse cardiovascular events by baseline estimated glomerular filtration rate: Pooled Hispanic subgroup analyses from the CANVAS Program and CREDENCE trial (2021) (1)
- Acute coronary syndromes: what have we learned about what we still need to know? (2006) (1)
- Clinical use of enoxaparin in the management of non-ST segment elevation acute coronary syndromes (2005) (1)
- EFFECTS OF SGLT2 INHIBITORS ON STROKE IN TYPE 2 DIABETES ACCORDING TO BASELINE KIDNEY FUNCTION (2020) (1)
- Reduction in recurrent ischemic events with vorapaxar: results from TRACER (2013) (1)
- Abstract 336: Real-World Experiences with Novel Anticoagulants for AF: Initial Insights from ORBIT-AF Phase II (2014) (1)
- Abstract 9992: Rhythm Control Versus Rate Control and Clinical Outcomes in Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) (2015) (1)
- Venous thromboembolism: yet another cardiovascular complication of chronic kidney disease? (2012) (1)
- 1123-P: Stress Cardiac Biomarkers and Adverse Cardiac Outcomes in the CANagliflozin CardioVascular Assessment Study (CANVAS) (2020) (1)
- SHORTER HOSPITAL STAYS AND OUTCOMES AFTER NON-ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (2014) (1)
- Author response for "The Effects of Canagliflozin on Heart Failure and Cardiovascular Death by Baseline Participant Characteristics: Analysis of the CREDENCE Trial" (2021) (0)
- Abstract 13006: High Use of Concomitant Antiplatelet Therapy with Oral Anticoagulation in Patients with Atrial Fibrillation: Results from the ORBIT-AF Registry (2012) (0)
- Abstract 325: Paradoxical Relationship Between Bleeding Risk, Stroke Risk, and Time in Therapeutic Range for Atrial Fibrillation Patients on Warfarin: Data from ORBIT-AF (2014) (0)
- Abstract 18194: Site Variation and Trends for Antithrombotic Therapy in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention in the VA System: Findings From the TREAT-AF Study (2017) (0)
- Independent predictors of heart failure in patients with type 2 diabetes and chronic kidney disease: modeling from the CREDENCE trial (2020) (0)
- 1130-P: Mediators of the Effects of Canagliflozin (CANA) on Heart Failure (HF) and CV Death in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD) (2020) (0)
- 131-LB: The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDENCE Trial (2021) (0)
- Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial (2022) (0)
- Heart Failure is Associated With Worse Quality of Life and Survival But Similar Stroke Risk in Atrial Fibrillation (2015) (0)
- Development of a novel biomarker-based clinical prediction model for major adverse cardiovascular events in revascularized patients with acute coronary syndromes (2015) (0)
- TCT-555 The Association of Health-Related Quality-of-Life Scores With Cardiovascular and Limb Outcomes in Patients With Symptomatic Peripheral Artery Disease: Insights From the EUCLID Trial (2019) (0)
- Abstract 16787: Use of Thienopyridine Prior to Presentation for Acute Coronary Syndromes and Association With Safety and Efficacy of Vorapaxar: Insights From the TRACER Study (2014) (0)
- Abstract 15123: Estimation of Stroke Outcomes in Atrial Fibrillation Using Continuous Clinical and Implantable Device Data From the Treat-AF Study: A Comparison With CHA2DS2-VASc Score (2018) (0)
- Abstract 057: Understanding of Treatment Strategies Among Patients Newly Diagnosed With Atrial Fibrillation: Findings From SATELITTE (2017) (0)
- Ankle-Brachial Index for Risk Stratification in Patients With Symptomatic Peripheral Artery Disease With and Without Prior Lower Extremity Revascularization (2021) (0)
- Abstract 112: Use of Evidence-Based Therapies in the Treatment of Cardiovascular Comorbidities and Risk Factors in Patients with Atrial Fibrillation: Findings From the ORBIT-AF Registry (2012) (0)
- Abstract 15813: Perioperative CK-MB Elevation is a Better Predictor of Survival Than New Q Waves Among Diabetic Patients With Multivessel Coronary Artery Disease Undergoing CABG (2013) (0)
- Clinical Features and Outcomes of Patients with Type 2 Myocardial Infarction : Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome ( TRACER ) (2017) (0)
- Abstract 15834: Evolution of Differences in Women and Men With Non-ST-Segment Elevation Acute Coronary Syndromes: Insights From Clinical Trials Over 15 Years (2013) (0)
- Abstract 16902: Efficacy and Safety of Rivaroxaban versus Warfarin in Patients Taking Non-dihydropyridine Calcium Channel Blockers: Results From the ROCKET AF Trial (2015) (0)
- Abstract 15659: Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Non-ST-Segment Elevation Acute Coronary Syndrome Patients in TRACER (2012) (0)
- Abstract 19349: Blood Pressure Control in Community Dwelling Patients with Atrial Fibrillation: Results from the ORBIT-AF Registry (2014) (0)
- ASSESSMENT OF STROKE RISK IN ATRIAL FIBRILLATION: PHYSICIAN ESTIMATE VERSUS CHADS2 RISK SCORE: RESULTS FROM ORBIT-AF (2014) (0)
- Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial (2021) (0)
- Impact of Polyvascular Disease and Diabetes on Limb and Cardiovascular Risk in Peripheral Artery Disease. (2022) (0)
- THE EFFICACY AND SAFETY OF CANGRELOR FOR PATIENTS UNDERGOING SINGLE VESSEL VERSUS MULTI VESSEL PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE CHAMPION PHOENIX TRIAL (2018) (0)
- EFFICACY OF CANGRELOR IN CONGESTIVE HEART FAILURE PATIENTS UNDERGOING PCI: A SUBGROUP ANALYSIS FROM THE CHAMPION POOLED DATABASE (2016) (0)
- Abstract P195: Long-Term Outcomes Associated with Hospital-Acquired Thrombocytopenia Among Patients with Acute Coronary Syndrome (2011) (0)
- Predictors of abrupt closure and consequences of emergency endpoints in the IMPACT II trial (1996) (0)
- Stroke and intracranial hemorrhage after reteplase or alteplase Results from the GUSTO-III trial (1997) (0)
- Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation the Investigators* (0)
- 139-LB: The Redox Balance Predicts Both Cardiovascular (CV) and Renal Outcomes in CANVAS (2020) (0)
- 27-OR: Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease (2020) (0)
- Abstract 14813: Pre-Treatment With Thienopyridines Reduces The Amount of Myonecrosis in Acute Coronary Syndrome Patients Invasively Managed: Insights from the CHAMPION trials (2010) (0)
- Abstract 1803: Catheterization without In-hospital Revascularization is Associated with Increased Long-term Mortality in Patients with Non-ST Elevation Myocardial Infarction and Significant Coronary Artery Disease (2007) (0)
- 1203-P: Cause of Hospitalizations in Patients with Type 2 Diabetes Mellitus (T2DM) in the CANVAS Program (2019) (0)
- Abstract 13963: Type 2 Myocardial Infarction: Incidence, Risk Factors, and Outcomes Among 41,581 Patients Enrolled in 3 Large Randomized Clinical Trials (2019) (0)
- Stroke Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and a History of Stroke or Transient Ischemic Attack (2012) (0)
- Abstract 18957: Rationale, Design, and Analysis of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R) - A Randomized, Placebo-Controlled Trial (2016) (0)
- Abstract 18938: Prognostically Important Myocardial Infarctions are Markedly Underreported in Patients Undergoing Percutaneous Coronary Intervention: Insights from CHAMPION PHOENIX (2014) (0)
- P1013CANAGLIFLOZIN AND RISK OF GENITAL INFECTIONS AND URINARY TRACT INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE- A POST-HOC ANALYSIS OF THE CREDENCE TRIAL (2020) (0)
- Letter by Matthews et al Regarding Article, "Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist". (2018) (0)
- Abstract 1519: Atrial Fibrillation Is Independently Associated With A High Risk of Death in Patients With Acute Coronary Syndromes (2007) (0)
- TREATMENT AND STROKE RISK IN LOW RISK CHA2DS2VASC ATRIAL FIBRILLATION PATIENTS: FINDINGS FROM THE ORBIT-AF REGISTRY (2016) (0)
- Abstract 17226: Latin American Patients With Atrial Fibrillation Have a Higher Risk Profile but Similar Response With Rivaroxaban versus Warfarin: A ROCKET AF Substudy (2017) (0)
- Atrial fibrillation: a spectrum of risk with a uniform treatment effect of novel anticoagulants? (2013) (0)
- Abstract 6180: Resolution of ST-Segment Depression: A New Prognostic Marker of Clinical Outcome in ST-Segment Elevation Myocardial Infarction (2008) (0)
- CARDIOVERSIONS AND ATRIAL FIBRILLATION: PATIENT OUTCOMES IN THE UNITED STATES: DATA FROM ORBIT-AF (2014) (0)
- Patients with Evolving Myocardial Infarction Have a Significant Missed Opportunity for Earlier Treatment: Experience from the SYNERGY Trial (2005) (0)
- Abstract 16169: Individual and Regional Determinants of Time in Therapeutic Range Among Patients Randomized to Warfarin in the ROCKET AF Trial of Rivaroxaban (2011) (0)
- OUTCOMES IN PATIENTS WITH A FAMILY HISTORY OF ATRIAL FIBRILLATION: FINDINGS FROM THE OUTCOMES REGISTRY FOR BETTER INFORMED TREATMENT OF ATRIAL FIBRILLATION (2015) (0)
- Abstract 77: Balancing Risks and Benefits of Anticoagulation Therapy in Atrial Fibrillation in Community Practice: Results from the ORBIT-AF Registry (2012) (0)
- THE EFFECT OF PLATELET INHIBITON BY CANGRELOR AMONG OBESE PATIENTS UNDERGOING CORONARY STENTING: INSIGHTS FROM THE CHAMPION TRIALS (2019) (0)
- J-SHAPED RELATIONSHIP BETWEEN RESTING HEART RATE AND MORTALITY IN PATIENTS WITH PERMANENT AF: RESULTS FROM THE OUTCOMES REGISTRY FOR BETTER INFORMED TREATMENT OF ATRIAL FIBRILLATION (ORBIT-AF) (2015) (0)
- 2135 Impact of primary care physician gatekeeping on medication prescriptions for atrial fibrillation (2018) (0)
- Abstract 14752: Canagliflozin Reduces Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Chronic Kidney Disease Regardless of Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial (2019) (0)
- Lessons learned from EVOLVE for the planning of future global randomized trials in chronic kidney disease (2016) (0)
- Abstract 16866: Blood Pressure Control and Stroke or Bleeding Risk in Patients with Atrial Fibrillation: Results from the ROCKET AF Trial (2014) (0)
- P1019CANAGLIFLOZIN AND RISK OF SKIN AND SOFT TISSUE INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE - A POST-HOC ANALYSIS OF THE CREDENCE TRIAL (2020) (0)
- P72 An iterative process for defining nonfatal endpoints in the context of clinical trials (1996) (0)
- Incidence of stroke in acute coronary syndromes without persistent ST- segment elevation (2000) (0)
- A46 Patient self-addressed postcard follow-up is inadequate: Results from the Duke Clinical Research Institute (1996) (0)
- 26-OR: Acute Declines in EGFR during Treatment with Canagliflozin and Its Implications for Clinical Practice: Insights from CREDENCE (2020) (0)
- Abstract 189: Why Digital Health Trials Can Fail: Lessons Learned from the SmartGUIDE Randomized Trial of Virtual Cardiac Rehabilitation (2019) (0)
- Abstract 15083: Selective Serotonin Reuptake Inhibitors Increase Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial (2016) (0)
- Abstract 17137: Renal Dysfunction is a Potent Predictor of Stroke and Systemic Embolism Among Individuals with Atrial Fibrillation: Results from the ROCKET AF Trial (2011) (0)
- Announcement (1976) (0)
- Author response for "SGLT2 inhibitors with and without metformin: a meta‐analysis of cardiovascular, kidney and mortality outcomes" (2020) (0)
- Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y12 inhibitors: Insights from the EUCLID trial (2021) (0)
- Glucose, insulin, and acute myocardial infarction: reply (2006) (0)
- COPD_A_292978 841..851 (2021) (0)
- Accelerated Epigenetic Aging Is Associated With Multiple Cardiometabolic, Hematologic, and Renal Abnormalities: A Project Baseline Health Substudy. (2023) (0)
- THE IMPACT OF TEMPORARY INTERRUPTIONS OF WARFARIN ON DOWNSTREAM TIME IN THERAPEUTIC RANGE IN PATIENTS WITH ATRIAL FIBRILLATION: RESULTS FROM ORBIT AF (2019) (0)
- Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial. (2023) (0)
- Abstract 5764: Discharge Without Antiplatelet Therapy After Inhospital Bleeding is an Independent Predictor of 6-Month Mortality Among Patients With Acute Coronary Syndrome: A Pooled Analysis From PURSUIT, PARAGON-A, PARAGON-B and SYNERGY (2009) (0)
- Risk factors for ischemic stroke in patients with acute myocardial infarction treated with thrombolytic therapy (1996) (0)
- Reviewing the role of healthy volunteer studies in drug development (2018) (0)
- ADHERENCE TO GUIDELINE RECOMMENDATIONS IN ATRIAL FIBRILLATION: FINDINGS FROM ORBIT-AF (2016) (0)
- Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation". (2016) (0)
- Design and development of a digital shared decision-making tool for stroke prevention in atrial fibrillation (2023) (0)
- BLOOD PRESSURE AND RISK FOR STROKE OR BLEEDING EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION: RESULTS FROM THE ORBIT AF STUDY (2015) (0)
- OUTCOMES OF CARDIAC CATH/PCI IN PATIENTS WITH AF: INSIGHTS FROM THE ORBIT II REGISTRY (2018) (0)
- Extremes of both weight gain and weight loss are associated with increased incidence of heart failure and cardiovascular death: evidence from the CANVAS Program and CREDENCE (2023) (0)
- Improved Cardiovascular and Renal Outcomes in the CANagliflozin CardioVascular Assessment Study (CANVAS) Program Irrespective of Baseline (BL) Body Mass Index (BMI) (2018) (0)
- Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet (2012) (0)
- EFFICACY OF A CENTRALIZED, BLENDED ELECTRONIC, AND HUMAN INTERVENTION TO IMPROVE DOAC ADHERENCE: THE SMARTADHERE TRIAL (2019) (0)
- 2259Ticagrelor in patients wtih symptomatic peripheral artery disease and prior coronary artery disease (2017) (0)
- PREDICTIVE VALUE OF EJECTION FRACTION AND RENAL FUNCTION IN HIGH RISK ACUTE CORONARY SYNDROME PATIENTS: RESULTS FROM THE SYNERGY TRIAL (2010) (0)
- 726 Acute Phase Inflammatory Biomarkers Add Little Predictive Value to Clinical Factors Plus NT-proBNP Among Patients With ST-Segment Elevation Myocardial Infarction: An Apex AMI Trial Substudy (2012) (0)
- P3797Increased risk of cardiovascular events and stroke among patients with atrial fibrillation and obstructive sleep apnea (2019) (0)
- P823Multiple biomarkers and cause-specific mortality in patients with acute coronary syndromes - Insights from the PLATO biomarker substudy (2018) (0)
- CHARACTERISTICS OF AF PATIENTS WITH LARGE IMPROVEMENT IN SYMPTOMS AT ONE YEAR: SUPER-RESPONSE IN THE ORBIT-AF REGISTRY (2019) (0)
- Abstract 15347: Symptom Status and Treatment Strategy in Contemporary Management of Atrial Fibrillation: Findings From the ORBIT-AF Registry (2011) (0)
- Clinical and echocardiographic diversity associated with physical fitness in the Project Baseline Health Study: implications for heart failure staging. (2023) (0)
- 4243 Developing clinical research units to improve quality, efficiency, and cost effectiveness within an academic institution (2020) (0)
- REDUCED IMMEDIATE ISCHEMIC EVENTS WITH CANGRELOR IN PCI USING THE UNIVERSAL DEFINITION OF MI: POOLED ANALYSIS OF THE CANGRELOR VERSUS STANDARD THERAPY TO ACHIEVE OPTIMAL MANAGEMENT OF PLATELET INHIBITION TRIALS (2011) (0)
- 19-OR: KidneyIntelX Association with Clinical Outcomes in Diabetic Kidney Disease (2022) (0)
- Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure (2022) (0)
- 133-LB: Canagliflozin Improves Cardiovascular and Renal Outcomes across Broad Geographic Regions: Results from CREDENCE (2021) (0)
- Differential Prognostic Implications of Peak Troponin Level in Acute Coronary Syndrome Treated With and Without Revascularization (2013) (0)
- PREDICTION OF MAJOR BLEEDING IN REVASCULARIZED PATIENTS WITH ACUTE CORONARY SYNDROMES: DEVELOPMENT OF A NOVEL BIOMARKER-BASED CLINICAL PREDICTION MODEL (2016) (0)
- LOST TO FOLLOW-UP IN CONTEMPORARY GLOBAL CARDIOVASCULAR RANDOMIZED CLINICAL TRIALS (2013) (0)
- Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS Program and CREDENCE. (2023) (0)
- P1028EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIFFERENT BASELINE LEVELS OF TYPE 2 DIABETES MELLITUS DISEASE SEVERITY: RESULTS FROM THE CANVAS PROGRAM (2020) (0)
- Canagliflozin and Cardiovascular (CV) Outcomes in Patients with Chronic Kidney Disease (2018) (0)
- The ARREST Pneumonia Clinical Trial (2021) (0)
- Unfractionated Heparin and Enoxaparin for the Management of Non-ST-Segment Elevation Acute Coronary Syndromes (2010) (0)
- Canagliflozin Reduces All-cause Hospitalization in Patients with Type 2 Diabetes Mellitus (2021) (0)
- NON VITAMIN K ORAL ANTICOAGULANTS ARE NOT ASSOCIATED WITH INCREASED RISK OF PERIOPERATIVE BLEEDING IN PATIENTS UNDERGOING CARDIAC SURGERY (2019) (0)
- Abstract 18703: Impact of the 2014 Atrial Fibrillation Guideline on the Proportion of Patients Recommended for Oral Anticoagulation (2014) (0)
- Relationship between diabetes, race, obesity and outcomes in patients with acute coronary syndrome: a pool analysis from randomized trials (2013) (0)
- Abstract 17152: Frequency and Management of Major Bleeding in Atrial Fibrillation Patients Treated With Warfarin and Non-vitamin K Oral Anticoagulants in Community Practice: Results From the ORBIT-AF II Registry (2015) (0)
- FP484DIFFERENT eGFR THRESHOLDS AND THE RENAL EFFECTS OF CANAGLIFLOZIN: DATA FROM THE CANVAS PROGRAM (2019) (0)
- Abstract 11910: The Systemic Inflammatory Response Syndrome is associated with Worse Outcomes in ST-Elevation Myocardial Infarction Patients: Insights from the CARDINAL Trial (2012) (0)
- SELECTION OF RATE VERSUS RHYTHM CONTROL FOR TREATMENT OF ATRIAL FIBRILLATION IN CLINICAL PRACTICE: RESULTS FROM THE ORBIT-AF REGISTRY (2012) (0)
- POLYVASCULAR DISEASE WITH AND WITHOUT DIABETES AND THE RISK OF ADVERSE CARDIOVASCULAR AND LIMB EVENTS IN THE EUCLID TRIAL (2020) (0)
- Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial (2022) (0)
- TREATMENT EFFECT OF CANAGLIFLOZIN FOR PATIENTS ON THERAPY FOR HEART FAILURE: POOLED ANALYSIS OF THE CANVAS PROGRAM AND CREDENCE TRIAL (2023) (0)
- IMPACT OF PERIPROCEDURAL MYOCARDIAL INFARCTION IN CONTEMPORARY PCI: POOLED PATIENT-LEVEL DATA FROM THE CHAMPION TRIALS (2017) (0)
- THE EFFICACY AND SAFETY OF CANGRELOR WITH AND WITHOUT GLYCOPROTEIN IIB/IIIA INHIBITORS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A POOLED ANALYSIS OF THE CHAMPION TRIALS (2016) (0)
- Which anticoagulant is best for ACS patients (2009) (0)
- Abstract 283: Association of Body Mass Index with Outcomes in Patients with Atrial Fibrillation: Results From the ORBIT-AF Registry (2015) (0)
- Yet Another Cardiovascular Complication of Chronic Kidney Disease? (2012) (0)
- Abstract 15956: Triple Versus Dual Antithrombotic Therapy in Patients With Atrial Fibrillation and History of Coronary Artery Disease: Insights From the ORBIT-AF Registry (2013) (0)
- Abstract 15115: Incidence, Timing, and Type of First and Recurrent Ischemic Events in Patients With and Without Peripheral Artery Disease After an Acute Coronary Syndrome (2017) (0)
- Abstract 10215: Predictors of Cause-Specific Hospitalization in US Outpatients With Atrial Fibrillation: Results From the ORBIT-AF Study (2013) (0)
- Abstract 16811: Who’s Left Behind? Characterization of Atrial Fibrillation Outpatients Eligible but Untreated With Oral Anticoagulation (2014) (0)
- Abstract 2059: Differences between Site-Reported and Core Laboratory Creatine Kinase-MB Values in an International Clinical Trial: Results from the SYNERGY Trial (2006) (0)
- Difference in causes of death between ticagrelor and clopidogrel in the PLATO trial (2013) (0)
- Characterization of cardiovascular endpoints, impact of event adjudication and effects of darapladib in the STABILITY trial (2015) (0)
- Efficacy and safety of cangrelor in patients with peripheral artery disease undergoing percutaneous coronary intervention – Insights from the CHAMPION program (2021) (0)
- Abstract 10: Contraindications to Oral Anticoagulation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) (2013) (0)
- Canagliflozin, mental health adverse events and diabetes: Exploratory analysis of the CREDENCE trial and CANVAS Program (2022) (0)
- 1098-82 Dynamic modeling of ST elevation acute myocardial infarction: Insights from COMMA (2004) (0)
- Abstract 127: Differences in Care Patterns, Health Status, and Outcomes of Atrial Fibrillation in Patients With and Without Diabetes: Findings From the ORBIT-AF Registry (2017) (0)
- ASSOCIATION BETWEEN ELEVATED B-TYPE NATRIURETIC PEPTIDE, DISEASE PROGRESSION, AND CLINICAL OUTCOMES AMONG PATIENTS WITH ATRIAL FIBRILLATION (2018) (0)
- arfarin Use and Outcomes in Patients with Atrial ibrillation Complicating Acute Coronary Syndromes (0)
- Glucose, insulin, and acute myocardial infarction. Authors' reply (2006) (0)
- Abstract 078: Implications of Patient-Reported Treatment Satisfaction for Discontinuation of Rivaroxaban versus Warfarin in ROCKET-AF (2017) (0)
- 1206-P: Effects of Canagliflozin (CANA) on Initiation of Insulin in CANVAS Program (2019) (0)
- 1216-P: The Effects of Canagliflozin on Uric Acid and Gout in Patients with Type 2 Diabetes in the CANVAS Program (2019) (0)
- CYP2C19 STATUS AND OUTCOMES IN THE EUCLID TRIAL (2018) (0)
- P31 Reliability of economic and quality of life data for collection of follow-up clinical outcome information (1996) (0)
- Abstract 6179: Baseline Q Trumps Time from Symptom Onset as a Prognostic Marker in STEMI Patients Treated with Primary PCI (2008) (0)
- P5198The occurrence of stroke and TIA in patients with peripheral artery disease and the effect of ticagrelor versus clopidogrel in EUCLID (2017) (0)
- Understanding Study Drug Discontinuation Through EUCLID (2022) (0)
- Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials). (2022) (0)
- Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome (2005) (0)
- Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors (2023) (0)
- TOTAL CARDIOVASCULAR AND LIMB EVENTS WITH TICAGRELOR AND CLOPIDOGREL IN PATIENTS WITH SYMPTOMATIC PAD IN THE EUCLID TRIAL (2022) (0)
- 321-OR: Effects of Canagliflozin (CANA) on Hospitalization for Heart Failure (HHF) by Baseline EGFR: Pooled Analysis from the CANVAS Program and CREDENCE (2021) (0)
- UNDETERMINED CAUSE OF DEATH: A POOLED ANALYSIS OF 9,307 DEATHS ACROSS 9 CARDIOVASCULAR TRIALS (2018) (0)
- 4065Moderate to severe renal insufficiency and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: the EUCLID trial (2018) (0)
- 747-P: Baseline Characteristics of Subjects in the Once-Weekly (OW) Semaglutide FLOW Kidney Outcomes Trial (2022) (0)
- Resolution of ST-Segment Depression: A New Prognostic Marker of Clinical Outcome in ST-Segment Elevation Myocardial Infarction (2008) (0)
- P71 Impact of the clinical events committee process on data safety monitoring (1996) (0)
- FC 089EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE ALBUMINURIA: INTEGRATED ANALYSES FROM THE CANVAS PROGRAM AND CREDENCE TRIAL (2021) (0)
- FC 123: Baseline Characteristics of the Flow Trial Population: Kidney Outcomes Trial With Once-Weekly Semaglutide in People With Type 2 Diabetes and Chronic Kidney Disease (2022) (0)
- Abstract 303: Adoption of the Novel Oral Anticoagulant Dabigatran in Patients with Atrial Fibrillation Receiving Warfarin in Community Practice: Findings from ORBIT AF (2013) (0)
- The development of a mobile app‐focused deduplication strategy for the Apple Heart Study that informs recommendations for future digital trials (2022) (0)
- Abstract 14185: Heart Failure Occurring at any Time During Hospitalization is Associated with Higher Mortality in Non-ST Elevation-Acute Coronary Syndromes (2011) (0)
- Medical Interventions in Unstable Angina: Does International Clinical Practice Match Evidence-Based Guidelines? (1997) (0)
- ASSOCIATION BETWEEN GUIDELINE-DIRECTED MEDICAL THERAPIES FOR COMORBID CONDITIONS AND CLINICAL OUTCOMES AMONG INDIVIDUALS WITH ATRIAL FIBRILLATION (2019) (0)
- CLINICAL FEATURES AND OUTCOMES OF PATIENTS WITH TYPE 2 MYOCARDIAL INFARCTION: INSIGHTS FROM THE TRACER TRIAL (2016) (0)
- revalence , Predictors , and Impact of onservative Medical Management for Patients ith Non – ST-Segment Elevation Acute Coronary yndromes Who Have Angiographically Documented ignificant Coronary Disease (2008) (0)
- Abstract 152: Persistence of Warfarin versus Dabigatran Therapy in Patients with Atrial Fibrillation: Results from the ORBIT AF Registry (2015) (0)
- Does Troponin Positivity Add Prognostic Value to Quantitative ST Segment Depression in Predicting Death and Myocardial Infarction in Non-ST Elevation Acute Coronary Syndrome Patients? (2002) (0)
- 1120-P: Association between the Inflammatory Marker GDF-15 and Kidney Disease Progression: Results from the CANVAS Trial (2020) (0)
- Abstract 14916: Adverse Event Reporting in >48,000 Participants in Four Acute Coronary Syndrome Trials (2015) (0)
- Enoxaparin vs Unfractionated Heparin in Acute Coronary Syndrome—Reply (2004) (0)
- IMPACT OF PRIOR CEREBROVASCULAR EVENTS ON ISCHEMIC AND BLEEDING OUTCOMES WITH CANGRELOR IN PERCUTANEOUS CORONARY INTERVENTION (2016) (0)
- IEWPOINT ationale and Strategies for Implementing ommunity-Based Transfer Protocols for rimary Percutaneous Coronary Intervention for cute ST-Segment Elevation Myocardial Infarction (2016) (0)
- Prognostic Signi fi cance of Bleeding Location and Severity Among Patients With Acute Coronary Syndromes (0)
- REDUCTION OF MYOCARDIAL INFARCTION WITH VORAPAXAR: RESULTS FROM THE TRA·CER TRIAL (2012) (0)
- Myocardial Infarction Treated With Thrombolysis : Results From GUSTO-I Risk Factors for In-hospital Nonhemorrhagic Stroke in Patients With Acute (1998) (0)
- Relatively Consistent Effects of Canagliflozin (CANA) on Outcomes Regardless of Baseline HbA1c in the CANagliflozin CardioVascular Assessment Study (CANVAS) Program (2018) (0)
- INCIDENCE AND PREDICTORS OF SUDDEN CARDIAC DEATH AFTER HOSPITALIZATION FOR NON-ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: AN ANALYSIS FROM THE TRACER TRIAL (2013) (0)
- 3111Genetic variability in PAR4 platelet response in relation to bleeding and ischemic outcomes: a genetic substudy of the TRACER trial (2017) (0)
- INCIDENCE AND IMPACT OF STENT THROMBOSIS DURING PERCUTANEOUS CORONARY INTERVENTION: COMPARISON OF CANGRELOR AND CLOPIDOGREL FROM THE CHAMPION PHOENIX TRIAL (2014) (0)
- NUISANCE BLEEDING IN ANTICOAGULATED PATIENTS WITH ATRIAL FIBRILLATION: INSIGHTS FROM THE OUTCOMES REGISTRY FOR BETTER INFORMED TREATMENT OF ATRIAL FIBRILLATION (ORBIT-AF) (2017) (0)
- 1224-P: Multidimensional Characterization of Prediabetes in the Project Baseline Health Study (2022) (0)
- Abstract 550: Prognostic Significance of Evolving ST-Segment Depression on Admission and Early Repeat Electrocardiograms in Non-ST Elevation Acute Coronary Syndromes - Insights from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitor (SYNERGY) (2008) (0)
- P3622Timing of trial stoppage for non-inferiority trials and interpretation: lessons from ROCKET AF (2017) (0)
- Abstract 16894: The Effect of Cangrelor on Cardiovascular and Bleeding Events in Patients With Peripheral Artery Disease - Insights From CHAMPION PHOENIX (2015) (0)
- The n e w e n g l a n d j o u r n a l of m e d i c i n e Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease (2017) (0)
- Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION (2022) (0)
- SOCIAL DETERMINANTS OF HEALTH AND CORONARY ARTERY CALCIUM: RESULTS FROM THE PROJECT BASELINE HEALTH STUDY (2023) (0)
- Contents (2020) (0)
- Abstract 15680: Sinus Node Dysfunction in Associated With Higher Symptom Burden and Increased Risk of Progression to Permanent Atrial Fibrillation: Results From ORBIT-AF Registry (2014) (0)
- CANAGLIFLOZIN AND RENAL OUTCOMES IN PATIENTS WITH CHRONIC KIDNEY DISEASE (2018) (0)
- 1118-102 Baseline white blood cell count and interleukin-6 levels provide complementary prognostic information in acute myocardial infarction: Results from the CARDINAL trial (2004) (0)
- Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial. (2023) (0)
- ROCKET-AF: Rivaroxaban Prevents Stroke as Effectively as Warfarin, with Lower Bleeding Risk (2010) (0)
- 755-6 Neurosurgical Evacuation for Intracranial Hemorrhage Associated with Improved Outcome in GUSTO (1995) (0)
- Abstract 17225: Therapeutic Strategies Following Major Bleeding in Atrial Fibrillation: Findings From ORBIT-AF (2015) (0)
- Abstract 17202: Comparative Performance of the R2Chads2, Chads2, and Cha2Ds2-vasc Scores in Atrial Fibrillation (2015) (0)
- The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA center dot CER) Trial (2011) (0)
- Does a clinical history of gout influence the relationship of serum uric acid levels and cardiovascular outcomes among patients with acute coronary syndromes (2016) (0)
- Abstract 17725: Frequency and Prognostic Importance of Troponin and CK-MB Elevations Following Coronary Artery Bypass Grafting: An Analysis from PRIMO I and PRIMO II (2012) (0)
- Cangrelor in Older Patients Results Association Between Age and Cardiovascular Events in CHAMPION PHOENIX (2017) (0)
- Chronic kidney disease is associated with worse outcomes in ACS patients: results from the TRACER trial (2014) (0)
- PHARMACODYNAMICS OF VORAPAXAR, A PLATELET PAR-1 ANTAGONIST, AND ITS INTERACTION WITH P2Y12 RECEPTOR PATHWAY IN THE TRACER TRIAL (2012) (0)
- Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: integrated analysis from the CANVAS Program and CREDENCE trial. (2023) (0)
- Effect of Temporary Interruption of Warfarin Due to an Intervention on Downstream Time in Therapeutic Range in Patients With Atrial Fibrillation (from ORBIT AF). (2020) (0)
- Acute Coronary Syndromes PHARMACODYNAMICS OF VORAPAXAR, A PLATELET PAR-1 ANTAGONIST, AND ITS INTERACTION WITH P2Y12 RECEPTOR PATHWAY IN THE TRA·CER TRIAL (2012) (0)
- Natural History and Outcomes of Patients with Critical Limb Ischemia in the Euclid Trial (2019) (0)
- Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial (2023) (0)
- Myocardial Enzyme Levels and Mortality After Coronary Artery Bypass Graft Surgery—Reply (2011) (0)
- Clinical validation of BARC definitions of bleeding after an ACS in the TRACER trial (2013) (0)
- 775-P: Effects of Canagliflozin (CANA) on Major Adverse Cardiovascular Events (MACE) by Baseline EGFR: Pooled Hispanic Subgroup Analysis from the CANVAS Program and CREDENCE (2021) (0)
- Destaques do VII international symposium of thrombosis and anticoagulation (ISTA) (2015) (0)
- P1627 Does infarct size measured by creatine kinase-MB predict clinical outcomes after fibrinolysis and primary percutaneous coronary intervention? (2003) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Kenneth W. Mahaffey?
Kenneth W. Mahaffey is affiliated with the following schools:
